Sividon Diagnostics GmbH

Second-generation gene expression tests for breast cancer compared: EndoPredict und PAM50

ASCO Recommends EndoPredict for Breast Cancer Diagnostics – Update of the Therapy Guideline for Biomarkers

Precision Diagnostics ‘Made in Germany’ Now Available In China – EndoPredict(R) Spares Breast Cancer Patients Unnecessary Chemotherapy

ESMO Guideline 2015: European Society for Medical Oncology recommends EndoPredict for breast cancer patients.

St. Gallen Brustkrebs Konferenz 2015: EndoPredict von internationalen Experten empfohlen

Breast cancer: Gene expression test EndoPredict predicts local recurrences

Update AGO Leitlinie 2015: EndoPredict(R) jetzt auch bei nodal-positiven Patientinnen empfohlen

Diagnosis and Treatment of Breast Cancer: EU research association proves the significance of the immune system in prognosis and treatment

Swiss Healthcare System to Reimburse Costs of EndoPredict from January 01st, 2015 on – Less Chemotherapy thanks to Gene Expression Test

San Antonio Breast Cancer Symposium 2015: EndoPredict prognostic after neoadjuvant chemotherapy and superior to commonly used markers

Therapy decision in breast cancer: EndoPredict(R) predicts benefit from chemotherapy – Independent research group confirms chemo benefit for high-risk patients

Genexpressionstest für Brustkrebspatientinnen: EndoPredict unabhängig vom Menopausenstatus der Patientinnen prognostisch

Expertengremium AGO bestätigt Nutzen von Genexpressionstests – Behandlungsleitlinien Brustkrebs 2014: EndoPredict wird mit einem ‘Plus’ empfohlen

Sividon Diagnostics und Myriad Genetics: Exklusive Vertriebspartnerschaft für EndoPredict

San Antonio Breast Cancer Conference 2013 – Second-Generation Gene Expression Tests Compared: Most prognostic information provided by EPclin

Chemotherapy for breast cancer: Taxane biomarkers successfully validated

ASCO 2013: New data on breast cancer prognosis tests – EndoPredict and uPA/PAI-1 compared